176 related articles for article (PubMed ID: 37973153)
1. Glucose metabolism-based signature predicts prognosis and immunotherapy strategies for colon adenocarcinoma.
Bai Z; Yan C; Nie Y; Zeng Q; Xu L; Wang S; Chang D
J Gene Med; 2024 Jan; 26(1):e3620. PubMed ID: 37973153
[TBL] [Abstract][Full Text] [Related]
2. Identification of a glycolysis- and lactate-related gene signature for predicting prognosis, immune microenvironment, and drug candidates in colon adenocarcinoma.
Liu C; Liu D; Wang F; Xie J; Liu Y; Wang H; Rong J; Xie J; Wang J; Zeng R; Zhou F; Peng J; Xie Y
Front Cell Dev Biol; 2022; 10():971992. PubMed ID: 36081904
[No Abstract] [Full Text] [Related]
3. Transcriptomic correlates of cell cycle checkpoints with distinct prognosis, molecular characteristics, immunological regulation, and therapeutic response in colorectal adenocarcinoma.
Wang H; Wang W; Wang Z; Li X
Front Immunol; 2023; 14():1291859. PubMed ID: 38143740
[TBL] [Abstract][Full Text] [Related]
4. Construction of a novel choline metabolism-related signature to predict prognosis, immune landscape, and chemotherapy response in colon adenocarcinoma.
Liu C; Liu D; Wang F; Liu Y; Xie J; Xie J; Xie Y
Front Immunol; 2022; 13():1038927. PubMed ID: 36451813
[TBL] [Abstract][Full Text] [Related]
5. An Intratumor Heterogeneity-Related Signature for Predicting Prognosis, Immune Landscape, and Chemotherapy Response in Colon Adenocarcinoma.
Liu C; Liu D; Wang F; Xie J; Liu Y; Wang H; Rong J; Xie J; Wang J; Zeng R; Zhou F; Xie Y
Front Med (Lausanne); 2022; 9():925661. PubMed ID: 35872794
[TBL] [Abstract][Full Text] [Related]
6. Developing a RiskS-core Model based on Angiogenesis-related lncRNAs for Colon Adenocarcinoma Prognostic Prediction.
Li X; Lei J; Shi Y; Peng Z; Gong M; Shu X
Curr Med Chem; 2023 Nov; ():. PubMed ID: 37961859
[TBL] [Abstract][Full Text] [Related]
7. Identification of a Four-Gene Metabolic Signature to Evaluate the Prognosis of Colon Adenocarcinoma Patients.
Zheng Y; Wu R; Wang X; Yin C
Front Public Health; 2022; 10():860381. PubMed ID: 35462848
[TBL] [Abstract][Full Text] [Related]
8. Lactate Metabolism-Associated lncRNA Pairs: A Prognostic Signature to Reveal the Immunological Landscape and Mediate Therapeutic Response in Patients With Colon Adenocarcinoma.
Xiao J; Wang X; Liu Y; Liu X; Yi J; Hu J
Front Immunol; 2022; 13():881359. PubMed ID: 35911752
[TBL] [Abstract][Full Text] [Related]
9. Metabolism-related lncRNAs signature to predict the prognosis of colon adenocarcinoma.
Sun Y; Liu B; Xiao B; Jiang X; Xiang JJ; Xie J; Hu XM
Cancer Med; 2023 Mar; 12(5):5994-6008. PubMed ID: 36366731
[TBL] [Abstract][Full Text] [Related]
10. Predictive Models for Colon Adenocarcinoma Diagnosis, Prognosis, and Immune Microenvironment Based on 2 Hypoxia-Related Genes: KDM3A and ENO3.
Kong C; Zheng L; Fang S; Chen M; Lin G; Qiu R; Zhao Z; Chen W; Song J; Yang Y; Ji J
Technol Cancer Res Treat; 2023; 22():15330338231195494. PubMed ID: 37650153
[No Abstract] [Full Text] [Related]
11. Development of a 5-mRNAsi-related gene signature to predict the prognosis of colon adenocarcinoma.
Huang H; Lu L; Li Y; Chen X; Li M; Yang M; Huang X
PeerJ; 2023; 11():e16477. PubMed ID: 38025763
[TBL] [Abstract][Full Text] [Related]
12. Identification of sixteen metabolic genes as potential biomarkers for colon adenocarcinoma.
Zhao F; Liu Y; Gu X; Zhang B; Song C; Cui B
J BUON; 2021; 26(4):1252-1259. PubMed ID: 34564978
[TBL] [Abstract][Full Text] [Related]
13. A Risk Model for Prognosis and Treatment Response Prediction in Colon Adenocarcinoma Based on Genes Associated with the Characteristics of the Epithelial-Mesenchymal Transition.
Huang H; Li T; Meng Z; Zhang X; Jiang S; Suo M; Li N
Int J Mol Sci; 2023 Aug; 24(17):. PubMed ID: 37686013
[TBL] [Abstract][Full Text] [Related]
14. A novel signature incorporating lipid metabolism- and immune-related genes to predict the prognosis and immune landscape in hepatocellular carcinoma.
Yang T; Luo Y; Liu J; Liu F; Ma Z; Liu G; Li H; Wen J; Chen C; Zeng X
Front Oncol; 2023; 13():1182434. PubMed ID: 37346073
[TBL] [Abstract][Full Text] [Related]
15. Based on cuproptosis-related lncRNAs, a novel prognostic signature for colon adenocarcinoma prognosis, immunotherapy, and chemotherapy response.
Li C; Zhang K; Gong Y; Wu Q; Zhang Y; Dong Y; Li D; Wang Z
Front Pharmacol; 2023; 14():1200054. PubMed ID: 37377924
[No Abstract] [Full Text] [Related]
16. A novel enterocyte-related 4-gene signature for predicting prognosis in colon adenocarcinoma.
Cheng X; Wei Y; Fu Y; Li J; Han L
Front Immunol; 2022; 13():1052182. PubMed ID: 36532007
[TBL] [Abstract][Full Text] [Related]
17. Identification of 9 Gene Signatures by WGCNA to Predict Prognosis for Colon Adenocarcinoma.
Yang M; He H; Peng T; Lu Y; Yu J
Comput Intell Neurosci; 2022; 2022():8598046. PubMed ID: 35392038
[TBL] [Abstract][Full Text] [Related]
18. In silico development and clinical validation of novel 8 gene signature based on lipid metabolism related genes in colon adenocarcinoma.
Jiang C; Liu Y; Wen S; Xu C; Gu L
Pharmacol Res; 2021 Jul; 169():105644. PubMed ID: 33940186
[TBL] [Abstract][Full Text] [Related]
19. Developing a prognosis and chemotherapy evaluating model for colon adenocarcinoma based on mitotic catastrophe-related genes.
Liu Y; Zhao Y; Zhang S; Rong S; He S; Hua L; Wang X; Chen H
Sci Rep; 2024 Jan; 14(1):1655. PubMed ID: 38238555
[TBL] [Abstract][Full Text] [Related]
20. A novel fatty acid metabolism-related gene signature predicts the prognosis, tumor immune properties, and immunotherapy response of colon adenocarcinoma patients.
Liu L; Liang L; Mai G; Chen Y
FASEB Bioadv; 2022 Sep; 4(9):585-601. PubMed ID: 36089979
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
